Cargando…

DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells

Metabolic alterations are well documented in various cancers. Non‐small‐cell lung cancers (NSCLCs) preferentially use lactate as the primary carbon source, but the underlying mechanisms are not well understood. We developed a lactate‐dependent cell proliferation assay and found that dynamin‐related...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Mangze, Zhao, Yu, Cao, Yuejiao, Tang, Qianru, Feng, Ziqin, Ni, Jun, Zhou, Xiaorong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540982/
https://www.ncbi.nlm.nih.gov/pubmed/32767829
http://dx.doi.org/10.1111/cas.14603
_version_ 1783591311419375616
author Hu, Mangze
Zhao, Yu
Cao, Yuejiao
Tang, Qianru
Feng, Ziqin
Ni, Jun
Zhou, Xiaorong
author_facet Hu, Mangze
Zhao, Yu
Cao, Yuejiao
Tang, Qianru
Feng, Ziqin
Ni, Jun
Zhou, Xiaorong
author_sort Hu, Mangze
collection PubMed
description Metabolic alterations are well documented in various cancers. Non‐small‐cell lung cancers (NSCLCs) preferentially use lactate as the primary carbon source, but the underlying mechanisms are not well understood. We developed a lactate‐dependent cell proliferation assay and found that dynamin‐related protein (DRP1), which is highly expressed in KRAS‐mutant NSCLC, is required for tumor cells to proliferate and uses lactate as fuel, demonstrating the critical role of DRP1 in the metabolic reprogramming of NSCLC. Metabolic and transcriptional profiling suggests that DRP1 orchestrates a supportive metabolic network to promote lactate utilization and redox homeostasis in lung cancer cells. DRP1 suppresses the production of reactive oxygen species (ROS) and protects cells against oxidative damage by enhancing lactate utilization. Moreover, targeting DRP1 not only reduces HSP90 expression but also enhances ROS‐induced HSP90 cleavage, thus inhibiting activation of mitogen activated protein kinase and PI3K pathways and leading to suppressed lactate utilization and increased ROS‐induced cell death. Taken together, these results suggest that DRP1 is a crucial regulator of lactate metabolism and redox homeostasis in KRAS‐mutant lung cancer, and that targeting lactate utilization by modulating DRP1 activity might be an effective treatment for lung cancer.
format Online
Article
Text
id pubmed-7540982
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75409822020-10-09 DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells Hu, Mangze Zhao, Yu Cao, Yuejiao Tang, Qianru Feng, Ziqin Ni, Jun Zhou, Xiaorong Cancer Sci Carcinogenesis Metabolic alterations are well documented in various cancers. Non‐small‐cell lung cancers (NSCLCs) preferentially use lactate as the primary carbon source, but the underlying mechanisms are not well understood. We developed a lactate‐dependent cell proliferation assay and found that dynamin‐related protein (DRP1), which is highly expressed in KRAS‐mutant NSCLC, is required for tumor cells to proliferate and uses lactate as fuel, demonstrating the critical role of DRP1 in the metabolic reprogramming of NSCLC. Metabolic and transcriptional profiling suggests that DRP1 orchestrates a supportive metabolic network to promote lactate utilization and redox homeostasis in lung cancer cells. DRP1 suppresses the production of reactive oxygen species (ROS) and protects cells against oxidative damage by enhancing lactate utilization. Moreover, targeting DRP1 not only reduces HSP90 expression but also enhances ROS‐induced HSP90 cleavage, thus inhibiting activation of mitogen activated protein kinase and PI3K pathways and leading to suppressed lactate utilization and increased ROS‐induced cell death. Taken together, these results suggest that DRP1 is a crucial regulator of lactate metabolism and redox homeostasis in KRAS‐mutant lung cancer, and that targeting lactate utilization by modulating DRP1 activity might be an effective treatment for lung cancer. John Wiley and Sons Inc. 2020-08-27 2020-10 /pmc/articles/PMC7540982/ /pubmed/32767829 http://dx.doi.org/10.1111/cas.14603 Text en © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Carcinogenesis
Hu, Mangze
Zhao, Yu
Cao, Yuejiao
Tang, Qianru
Feng, Ziqin
Ni, Jun
Zhou, Xiaorong
DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells
title DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells
title_full DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells
title_fullStr DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells
title_full_unstemmed DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells
title_short DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells
title_sort drp1 promotes lactate utilization in kras‐mutant non‐small‐cell lung cancer cells
topic Carcinogenesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540982/
https://www.ncbi.nlm.nih.gov/pubmed/32767829
http://dx.doi.org/10.1111/cas.14603
work_keys_str_mv AT humangze drp1promoteslactateutilizationinkrasmutantnonsmallcelllungcancercells
AT zhaoyu drp1promoteslactateutilizationinkrasmutantnonsmallcelllungcancercells
AT caoyuejiao drp1promoteslactateutilizationinkrasmutantnonsmallcelllungcancercells
AT tangqianru drp1promoteslactateutilizationinkrasmutantnonsmallcelllungcancercells
AT fengziqin drp1promoteslactateutilizationinkrasmutantnonsmallcelllungcancercells
AT nijun drp1promoteslactateutilizationinkrasmutantnonsmallcelllungcancercells
AT zhouxiaorong drp1promoteslactateutilizationinkrasmutantnonsmallcelllungcancercells